U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07471074) titled 'Phenotypic and Functional Study of Bone Marrow Mesenchymal Stem Cells in Waldenstrom Macroglobulinemia' on March 10.
Brief Summary: Waldenstrom disease (WM) is defined by the presence of bone marrow lymphoplasmocytes and monoclonal immunoglobulin M (IgM). Treatment should be initiated in cases of cytopenia, tumor syndrome or when the physicochemical or immunological properties of IgM explain the occurrence of amyloidosis, cryoglobulin or neurological manifestations, which have already been extensively studied. The disease is characterized by a MYD88 emutation found in 90% of patients. However, the molecular landscape is complex: th...